Participants 51 82 4
small cell lung cancer patients
Participants 195 234 5
small cell lung cancer (SCLC) patients,
Participants 323 572 5
trial, 11 patients received either standard (four weekly) chemotherapy with ifosfamide, carboplatin, and etoposide (ICE) or accelerated (two weekly) ICE with filgrastim (granulocyte colony-stimulating factor [G-CSF]) and autologous stem cell support
